Wednesday, April 09, 2008

Caffeine Prevents Multiple Sclerosis-like Disease In Mice





ScienceDaily (Apr. 8, 2008) — Mice given caffeine equivalent to a human drinking six to eight cups of coffee a day were protected from developing experimental autoimmune encephalomyelitis (EAE), the animal model for the human disease Multiple Sclerosis (MS), according to researchers at Cornell University.

Caffeine is a well-known adenosine receptor blocker, and the researchers believe results show the importance of this molecule in permitting the infiltration of immune cells into the central nervous system of patients with MS.

Multiple sclerosis is an autoimmune disease of the central nervous system (CNS) that occurs when the body's immune system attacks and damages nerves in the brain and spinal cord. The infiltration of immune cells into brain and other CNS tissue is rarely seen in healthy individuals without MS. What allows the immune cells to infiltrate the CNS tissue of patients with MS is unknown. In earlier work, Dr. Margaret S. Bynoe became convinced that the molecule adenosine is responsible for this infiltration.

Adenosine is widely present in the body and plays an important role in many biochemical processes, such as energy transfer and the promotion of sleep and suppression of arousal. The researchers' first studies found that mice that lacked CD73, the enzyme necessary for synthesizing extracellular adenosine, were protected from developing the mouse form of MS (experimental autoimmune encephalomyelitis or EAE).

Additional studies involving immune cells from mice that lack CD73 further convinced them that normal CD73's ability to synthesize extracellular adenosine was what was important for development and progression of the MS-like disease. That helped explain the presence of adenosine near the cells, but how did the compound get into the CNS cells? Since adenosine must bind to its receptor in order to affect a cell, the researchers reasoned that perhaps adenosine receptor activation was what allowed for entry of immune cells into the brain and spinal cord. To test that idea in the study presented at Experimental Biology 2008, they turned to caffeine.

Dr. Jeffrey H. Mills, a postdoctoral associate in the laboratory of Dr. Margaret S. Bynoe, presented the findings at Experimental Biology 2008 on April 7. The presentation was part of the scientific programs of the American Society of Immunologists.
Caffeine's stimulatory effects on the CNS are in large part due to its ability to bind to the same receptors as adenosine, thus blocking adenosine's ability to affect CNS cells. Mice that consumed caffeine in their drinking water were protected from development of EAE, the MS model. Dr. Bynoe concludes that these experiments show that CD73 and adenosine receptor signaling are required for the efficient entry of immune cells into the CNS during the initiation and progression of EAE in mice and, quite possibly, during the development of MS in humans.

Dr. Bynoe adds, "These results might mark the first in a series of discoveries from our lab that could spawn the impetus for the development of adenosine-based therapies for the treatment of MS."

In addition to Dr. Mills and Dr. Bynoe, coauthors of the paper include Dr. Cynthia Mueller and Dr. Adam Waickman, also of Cornell, and Dr. Linda F. Thompson, at the Oklahoma Medical Research Foundation. This work was funded by the National Institutes of Health.

Adapted from materials provided by Federation of American Societies for Experimental Biology, via EurekAlert!, a service of AAAS.

NovaDel Announces Positive Data from Pilot Pharmacokinetic Study Comparing Tizanidine Oral Spray to Zanaflex(R) Tablets





FLEMINGTON, N.J., Apr 07, 2008 (BUSINESS WIRE) --

NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today announced pharmacokinetic (PK), pharmacodynamic (PD) and safety results from its Pilot PK Study of its Oral Spray formulation of tizanidine compared to tizanidine tablets marketed as Zanaflex(R). Tizanidine is a leading drug indicated for the management of spasticity. Spasticity is a condition manifested in various neurological disorders, such as multiple sclerosis, stroke, cerebral palsy and spinal cord injury. This study demonstrates drug delivery across the oral mucosa, achieving faster entry of drug into the bloodstream with greater bioavailability and importantly in this particular disorder, avoiding the need to swallow a tablet or capsule.

Objectives of the Study
This Pilot Pharmacokinetic Study was designed to compare the PK profile of 2 mg, 4 mg and 8 mg Oral Spray (OS) doses of tizanidine hydrochloride to a 4 mg Zanaflex(R) (tizanidine hydrochloride) tablet dose in healthy male volunteers under fasting conditions. Assessment of the PD properties of tizanidine OS was made by administering the Digit Symbol Substitution Test (DSST) and measuring drowsiness levels via a self-assessment scale and changes in blood pressure and pulse rate associated with study drug administration. Safety and tolerability information was also collected.

Results of the Study
The data show substantially greater exposure to tizanidine from the OS formulations and earlier detectable plasma drug levels for OS doses versus the tablet (approximately 10 minutes and 17 minutes respectively, where p values ranged from 0.0002 to 0.0117). When dose normalized (to 4 mg), the bioavailability of the tizanidine OS doses were 2.04 to 3.49-fold greater than that of the 4 mg tablet.

The 2 mg oral spray and 4 mg tablet doses gave comparable results in the DSST test where positive scores were observed compared to baseline. There was an apparent decrease in the DSST scores after administration of the 4 mg and 8 mg OS study drugs. A decrease in the DSST score indicates a decrease in attention, perceptual speed, motor speed, visual processing and memory. Self-assessment of drowsiness indicated that subjects dosed with either the 4 mg or 8 mg OS assessed themselves as being "a bit more" or "much more" sleepy/drowsy than they were at baseline at a frequency comparable to that reported for the tablet. Reductions in blood pressure and pulse rate, recognized side effects of tizanidine, were observed with all doses of tizanidine OS and the tablet.

A total of 3 subjects had Adverse Events (AEs) of mild or moderate bradycardia and hypotension, which are well-recognized side effects of tizanidine, after the highest dose of tizanidine OS (8 mg). No subjects prematurely discontinued from the study due to AEs, and there were no Serious Adverse Events (SAEs) or deaths. No subjects reported any symptoms in the oral cavity. These results indicate that tizanidine OS is a well tolerated and safe based on the relatively small number of reported AEs and the absence of any SAEs both locally and systemically.

"These results further demonstrate the potential of our technology to rapidly deliver a variety of drugs across the oral mucosa" commented Mr. Steven Ratoff, NovaDel's Chairman of the Board and Interim President & Chief Executive Officer. "These results indicate that substantially greater bioavailability can be achieved with tizanidine in an oral spray form which may offer the opportunity for a product with an improved safety and side effect profile compared to tablets."

ABOUT THE STUDY
This was a single-center, 4-way crossover, open-label, dose-ranging, multiple-treatment PK study in healthy male volunteers 18 to 40 years old. There were 14 subjects planned; 14 subjects enrolled. Data from 14 subjects were evaluable for PK, pharmacodynamic and safety analyses. Treatments were separated by a period of 7 (+/- days). Blood samples (5.5 ml/sample) for PK evaluation were collected at each visit.

The OS test article used in this study has greater than 12 months physical and chemical stability and was supplied in 2 mg, 4 mg and 8 mg strengths. The tizanidine tablet was supplied from commercial sources as Zanaflex(R) from Acorda Therapeutics, Inc.

Measurements:
Pharmacokinetic: Maximum drug concentration (C(max)); time to maximum drug concentration (T(max)), time to detectable drug concentration (T(det)); elimination rate constant (K(e)); bioavailability (relative to the oral tablet); elimination half-life (t(1/2)); absorption t(1/2); area under the concentration time curve (AUC), including AUC(0-T), calculated from time 0 to the last non-zero concentration (C(T)), AUC(0-Infinity), calculated by extrapolation of AUC(0-T) to infinity by adding C(T)/K(e) to AUC(0-T); clearance (CL/F), clearance corrected for body weight (CL/F/kg); volume of distribution (Vd/F) and volume of distribution corrected for body weight (V(d)/F).

Pharmacodynamic: Digit Symbol Substitution Test (DSST), self-assessment of drowsiness, blood pressure (BP), and pulse rate.
Safety: Changes in physical examinations, including oral soft tissue examinations at after each lingual spray dosing, laboratory parameters, adverse events (AEs), and vital signs.

ABOUT SPASTICITY
Spasticity affects over 500,000 people in the U.S. alone. Spasticity is not a disease, but rather a symptom of various neurological disorders, including, but not limited to multiple sclerosis (MS), spinal cord injury, stroke and cerebral palsy. These disorders cause a change in the balance of signals between the central nervous system and the muscles. This imbalance leads to involuntary tensing, stiffening and contracting of muscles. Tizanidine is the most widely prescribed treatment for spasticity with approximately 4 million prescriptions written annually.

ABOUT NOVADEL PHARMA
NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed drugs. The Company's proprietary technology offers, in comparison to conventional oral dosage forms, the potential for faster absorption of drugs into the bloodstream leading to quicker onset of therapeutic effects and possibly reduced first pass liver metabolism, which may result in lower doses. Oral sprays eliminate the requirement for water or the need to swallow, potentially improving patient convenience and adherence.

NovaDel's oral spray technology is focused on addressing unmet medical needs for a broad array of existing and future pharmaceutical products. The Company's most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system. NovaDel plans to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. To find out more about NovaDel Pharma Inc. (AMX: NVD), visit our website at www.novadel.com.

FORWARD-LOOKING STATEMENTS:
Except for historical information contained herein, this document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the successful completion of its pilot pharmacokinetic feasibility studies, the ability to develop products (independently and through collaborative arrangements), the ability to commercialize and obtain FDA and other regulatory approvals for products under development and the acceptance in the marketplace for oral spray products. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings. Zanaflex(R) is a registered trademark of Acorda Therapeutics, Inc.

SOURCE: NovaDel Pharma Inc.
NovaDel Pharma Inc. Michael E. Spicer, 908-782-3431 ext. 2550 Chief Financial Officer mspicer@novadel.com
Copyright Business Wire 2008


Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings.

Please note that the information in each of the press releases referenced here is only current as of the date of the release. NovaDel Pharma Inc. undertakes no obligation to update the information in the press releases to reflect new information, the occurrence of future events or circumstances, or otherwise.

MediciNova Reports Clinical Results from





- MN-166 Slows Disability Progression; Significant Neuroprotective Effects Observed by MRI -

SAN DIEGO, Calif. – April 7, 2008 – MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today
announced positive clinical findings from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis (MS). The second year findings expand upon the results from the first year of this study reported previously. MN-166 treatment resulted in positive findings on three independent measures indicative of a potential disease-progression modifying effect. The findings include:

• Sustained disability progression was significantly less likely (by approximately 50 percent) in those patients receiving MN-166 at either 30 or 60 mg per day for 24 months than in those patients receiving the drug for 12 months (p=0.026). Sustained disability progression was measured as a greater than or equal to 1.0 point increase from baseline in the Expanded Disability Status Scale (EDSS) score for four consecutive months. This positive clinical finding was corroborated by positive findings on two separate radiologic measures.

• The clinical trial demonstrated that the significant reduction in brain volume loss (p=0.035), as measured by cranial magnetic resonance imaging (MRI) scans, observed after 12 months in patients treated with 60 mg per day of MN-166
compared to placebo was again demonstrated in year two of the study. Brain volume loss was significantly less (p=0.030) in patients receiving 60 mg per day of MN-166 for 24 months compared to the other treatment groups, for more information on Percent Brain Volume loss for each of the treatment groups in year two of the study, see graph:

PERCENT BRAIN VOLUME LOSS AT 24-MONTHS





• MN-166 treatment at 60 mg per day significantly reduced the relative risk for conversion of new inflammatory lesions identified at month two to Persistent Black Holes (PBH), an MRI indicator of neuronal loss, eight months later at month ten by 37 percent (p=0.011); such lesions that remain unchanged for eight months are considered PBHs as compared to transient inflammatory lesions that are more closely associated with relapses. MN-166 treatment at 30 mg per day resulted in a trend toward reducing evolution to PBH (p=0.074). Loss of brain volume and development of PBHs on MRI have been shown to correlate with clinical progression and disability in MS patients. MN-166 was well tolerated at all doses over the 24 months of this clinical trial. Of the 297 patients enrolled in the study, 82.5 percent, or 245 patients, completed the full 24 months of the study. The most common adverse events possibly related to MN-166 included mild, transient gastrointestinal disturbances and depression.

“After an extensive review of these data our Scientific Advisory Board recommended that MN-166 be advanced into pivotal design studies with clinical and MRI evaluations of MS progression as the primary objectives,” said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc. “The significant favorable effects on measures of disability progression and reduced neuronal damage observed in this study are quite exciting and representative of the type of new treatment being sought by the MS scientific community according to our advisors. We are excited to be part of advancing MS treatment in a new direction and look forward to confirming these findings in future clinical trials with the assistance of a corporate partner.”

The two-year randomized, double-blind, placebo-controlled Phase II clinical trial included 297 patients with relapsing MS. In the second year of the study, all patients were on drug. Patients who received 30 or 60 mg of MN-166 per day during the first 12 months of the study remained on the assigned dose for the second 12 months of the study; patients who received placebo during the first 12 months of the study were randomized to receive either 30 or 60 mg of MN-166 per day (double-blind maintained) during the second 12 months of the study. Clinical and radiological outcomes were evaluated. First-year efficacy results of this clinical trial were announced in March 2007 and described more completely at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in November 2007. Briefly, MN-166 at 60 mg per day significantly reduced brain volume loss by 33 percent and median time to first relapse by 157 days compared to placebo. The median time to first on-study relapse was 244 days for placebo, 255 days on MN-166 at 30 mg per day and 401 days (which could only be calculated after the full study unblinding) on MN-166 at 60 mg per day. MN-166 did not significantly reduce cumulative brain lesion count on MRI in year one of this clinical trial, which was the protocol-defined primary endpoint of the study.

About MN-166
MN-166 is a novel, orally administered compound being evaluated for the treatment of MS. MN-166 increases the release of neuronal growth factors and inhibits leukotriene activity, phosphodiesterases and nitric oxide synthase. MN-166 may also suppress the production of pro-inflammatory cytokines (IL-1β, TNF-α) and may enhance the production of the anti inflammatory cytokines (IL-4, IL-10). MediciNova acquired an exclusive, worldwide (excluding Japan, China, Taiwan and South Korea), sublicensable license to MN-166 for the treatment of MS, excluding ophthalmic solution formulations, from Kyorin Pharmaceutical Co. Ltd. For the past 18 years, MN-166 has been marketed in Japan and South Korea as Ketas® for the treatment of asthma and cerebrovascular disorders. Data from the existing clinical trial and postmarketing surveillance databases, which includes treatment of an estimated 3.2 million patients with these disorders, indicate that Ketas® is well tolerated.

About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova’s current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline: MN-221 for the treatment of status
asthmaticus, an acute, severe asthma attack, and MN-166 for the treatment of multiple sclerosis. MediciNova will seek to monetize its other product candidates at key value inflection points. For more information on MediciNova, Inc., please visit
www.medicinova.com.

Statements in this press release that are not historical in nature constitute forwardlooking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include,
without limitation, statements regarding MediciNova’s clinical trials supporting safety and efficacy of product candidates and the potential novelty of such product candidates as treatments for disease, plans and objectives for present and future clinical trials and product development, strategies, future performance, expectations, assumptions, financial condition, liquidity and capital resources. These forward-looking statements may be preceded by, followed by or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “would,” or similar expressions.

These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forwardlooking statements, include, but are not limited to, the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities, the timing of expected filings with the FDA, MediciNova’s failure to execute strategic plans or strategies successfully, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and MediciNova’s ability to raise sufficient capital when needed, intellectual property or contract rights, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2007. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

Friday, March 21, 2008

Biogen's Tysabri to get liver warning in Europe





Thursday, March 20, 2008 - 2:57 PM EDT

On the heels of a similar decision by the U.S. Food and Drug Administration, European regulators have concluded that patients should be warned about possible liver damage related to the Biogen Idec drug Tysabri.

Tysabri, which Massachusetts-based Biogen Idec (Nasdaq: BIIB) makes at a facility in Research Triangle Park, is a drug used to treat multiple sclerosis.

On Feb. 27, Biogen and its Irish partner on Tysabri, Elan Corp., posted a letter to the FDA's Web site. The letter, addressed to doctors, says patients have developed signs of liver injury as soon as six days after taking their first dose of the drug. It tells doctors that they need to monitor Tysabri patients for potential liver damage and warn them about the risk.

Now, the European Medicines Agency is addressing the issue. In a statement Thursday, it also says that Tysabri patients need to be monitored for and warned about liver damage.

Tysabri is Biogen's fastest-growing drug. It was pulled from the market in 2005 after it was linked to a rare but fatal brain infection. U.S. regulators allowed it to return under a monitoring program in 2006, however, after they decided that the drug's effectiveness outweighed its risks.

EMEA says Elan and Biogen's Tysabri should carry liver injury warnings





03.20.08, 12:44 PM ET

LONDON (Thomson Financial) - The European Medicines Agency EMEA has announced the labels for Elan and Biogen's Tysabri should include warnings about liver injury on its product information.

The EMEA's Committee for Medicinal Products for Human Use has requested that Elan (nyse: ELN - news - people ), the marketing authorisation holder for Tysabri, submits a variation to the marketing authorisation to implement these changes.

Last month Elan and Biogen announced some patients suffered liver injury after taking the multiple sclerosis treatment.

Copyright Thomson Financial News Limited 2008. All rights reserved.

The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

Neither the Subscriber nor Thomson Financial News warrants the completeness or accuracy of the Service or the suitability of the Service as a trading aid and neither accepts any liability for losses howsoever incurred. The content on this site, including news, quotes, data and other information, is provided by Thomson Financial News and its third party content providers for your personal information only, and neither Thomson Financial News nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon.

EU agency backs Novartis drug Extavia for M





LONDON, March 20 (Reuters) - The European Medicines Agency has recommended approval of Novartis' (NOVN.VX: Quote, Profile, Research) Extavia intended for treatment of people with multiple sclerosis, the London-based watchdog said on Thursday.

Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

The drug is the company's branded version of Bayer AG's (BAYG.DE: Quote, Profile, Research) Betaseron, interferon beta-1b, that gives Novartis an important presence in MS treatment before the anticipated submission of its once-daily therapy FTY720 (fingolimod).

Last March Novartis and Bayer settled a dispute over Betaseron in a deal that gave Bayer full control of the product while allowing Novartis to launch a version in 2009.

Multiple sclerosis affects more than an estimated 2.5 million patients worldwide and is one of the leading causes of neurological disability in young adults. (Reporting by Michael Kahn; Editing by Rory Channing)

© Reuters 2008 All rights reserved

Biogen Idec CEO predicts more brain disorders in Tysabri patients





Tuesday, March 18, 2008

The CEO of Biogen Idec told investors Tuesday that he expects to see more cases of a rare, fatal brain disorder in patients taking the drug Tysabri, Reuters reported Tuesday.

But James Mullen, the executive, thinks the problems are unlikely to create more regulatory problems for Tysabri, a multiple sclerosis drug pulled temporarily from the market in 2005 thanks to the brain disease.

James Mullen told investors that "we anticipate there will be some additional cases of PML," according to Reuters. PML is the abbreviation for the brain infection seen in two Tysabri patients three years ago. Biogen Idec (Nasdaq: BIIB), which makes the drug at a facility in Research Triangle Park, voluntarily pulled the treatment from the market.

Tysabri has since returned under a patient-monitoring program, however, with no new cases of PML. Biogen hopes to make it a blockbuster, billion-dollar drug by 2010.

New cases of PML in Tysabri patients could "create a lot of excitement in the short term given the history of this product," Reuters reported Mullen as saying. But the Biogen chief added that he would see "no regulatory problems." Many patients take Tysabri despite its risks because the drug is highly effective.

Biogen co-markets Tysabri with Elan Corp. of Ireland.

Contact the Editor Need Assistance? More Latest News

Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Mu





WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Teva Pharmaceutical's Copaxone has the greatest patient share among first- and second-line therapies, and falls short of Merck Serono/Pfizer's Rebif (by 0.2 percent) in third-line treatment. However, in all three lines of therapy, the interferon-beta drug class (Biogen Idec's Avonex, Rebif, and Berlex's Betaseron) outpaces the altered peptide ligand drug class (consisting only of Copaxone) in patient share. Competition between the two drug classes is fiercest in first-line therapy.

"The low volume of patient share attributed to Avonex or Rebif compared with Copaxone in first- and second-line treatment illustrates a significant delay on the part of physicians and/or patients to engage in an interferon- beta therapy within a year of a patient's initial diagnosis for multiple sclerosis," said Madhuri Borde, analyst at Decision Resources. "However, the magnitudes of Rebif's first- and second-line patient shares suggest that some physicians are treating the disease more aggressively than might be expected, as this high-dose, high-frequency agent reaches patient shares close to and surpassing Avonex in first- and second-line treatment, respectively."

According to the new report entitled Treatment Algorithms in Multiple Sclerosis, neurologists note that Copaxone's better short-term and long-term side-effect/safety profile, together with its lower rate of induction of neutralizing antibodies, are critical reasons for choosing Copaxone instead of Avonex, Rebif and Betaseron. Although Copaxone is administered daily, 23-28 percent of neurologists we surveyed indicate that a key reason to prescribe the drug over any of the interferon-beta therapies is the drug's ability to foster greater patient compliance, an attribute that is closely tied to the Copaxone's lower incidence of flulike side effects.

About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

-- Summary of U.S. medical practice based on interviews with leading experts in the field. -- Qualitative diagnosis/referral/treatment algorithm for the United States. -- Drug usage by lines of therapy (1st, 2nd, 3rd line). -- Discussion of key freeform combinations by lines of therapy. -- Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line). -- Progression of therapy from key 1st line products. -- Pathway to key therapies from previous therapies. -- Qualitative analysis of two-year forecast incorporating upcoming launches, changes in reimbursement, etc.

About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources

Old drug, new use? Naltrexone in tiny doses shows promise in treating autoimmune diseases





By Bill Kettler
Mail Tribune
March 10, 2008

When Destiny Marquez finds a good thing, she wants other people to know about it.

These days the Medford woman has been talking to anyone who will listen about a drug called naltrexone. It's been widely used to treat opiate addiction, but that's not what captured her interest.

Marquez came across naltrexone while she was trying to help her father, Bentley Lyon, who's been struggling with Parkinson's disease for 18 years. His symptoms had been increasing, and he started to decline rapidly after suffering a stroke during surgery.

A friend had told Marquez that she'd heard some Parkinson's patients were getting relief from their symptoms by taking extremely low doses of naltrexone, or LDN. Marquez and her mother, Elizabeth, balked. Although the drug had been tested and approved by the federal Food and Drug Administration for addiction treatment, it had never been tested for treating Parkinson's.

"We said 'No,' " Marquez recalled.

When Bentley's condition continued to deteriorate, mother and daughter asked him to give LDN a try. By then they had done some research on their own, and learned that the drug was gaining favor not only among Parkinson's patients, but also as a treatment for other diseases, including multiple sclerosis and Crohn's disease.

Marquez said her father started taking 3 mg a day late in 2004, far less than the 50 mg that's prescribed for addiction treatment.

"It was like a miracle," she recalled.

Marquez said the spasticity in her father's left leg disappeared over several days, and his caregiver said he stopped complaining about back pain.

Speech is difficult for Bentley, 78, a former Marine and marathon runner who worked as a forester and wrote two mystery novels, but he said LDN "stopped the progression" of his symptoms. Naltrexone apparently works by stimulating the body's own immune system, said Dr. Ian Zagon, a professor of neural and behavioral sciences at Pennsylvania State University.

"It's very simple," he said, "but it took a while to figure out."

Zagon said research over the past two decades indicates the body's immune system is orchestrated by its own naturally produced internal opioids. Large doses of naltrexone block the body's opioid receptors, eliminating the high derived from drugs. In extremely small doses, however, naltrexone seems to block the opioid receptors just long enough to prompt the body's hormone system to produce more of its own natural endorphins, which somehow encourages the immune system.

"We're working with the body's own chemistry," Zagon said. "This has nothing to do with chemotherapy."

The drug's off-label use began to grow just as the Internet became a major source of information exchange. There's now an LDN home page (www.lowdosenaltrexone.org), a Wikipedia entry, and forum pages where people exchange information and their own experiences with the drug.

Naltrexone's efficacy for Parkinson's or other autoimmune diseases could be established by subjecting it to a new round of clinical trials, the same rigorous, expensive, time-consuming studies that were performed when it was approved for addiction treatment. Unfortunately, there's little incentive for drug manufacturers to spend the money. Naltrexone has gone generic, and lost the patent protections that would make it a profitable drug for treating autoimmune diseases.

"It doesn't behoove the pharmaceutical companies to develop it," Zagon said.

As a generic drug, it's also incredibly cheap. Most patients can get it for about $1 a day.

Zagon would like to see someone provide the funding for new clinical trials for LDN, but in the meantime, some studies are already under way. The National Multiple Sclerosis Society has funded a study that will look at high- and low-dose naltrexone treatments in mice with a disease much like multiple sclerosis, and the National Institutes of Health has funded a phase II trial using LDN in patients with Crohn's disease. Phase II trials involve as many as several hundred people, but they fall short of the randomized phase III trials in which some people get the drug and others do not.

Marquez has seen how the drug has helped her father, and she hopes one day someone will do the research that will determine its efficacy.

"We're not the only family talking about this," she said. "We're trying to share this information because it buys you time.

"We've got to tell the world this drug is incredible."

Destiny Marquez can be reached by e-mail at: destinyellen@yahoo.com

Reach reporter Bill Kettler at 776-4492 or e-mail: bkettler@mailtribune.com

Pixantrone to be studied in phase I/II trial for aaggressive multiple sclerosis





Preclinical profile and potential for lower cardiac toxicity drives investigator interest

SEATTLE, March 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that its investigational drug pixantrone will be studied in a multicenter phase I/II trial initiated by the Fondation Charcot Stichting, in Brussels, Belgium, which sponsors a consortium of centers involved in studying new therapies for the treatment for multiple sclerosis. This study will enroll patients with aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). Mitoxantrone, a related compound which is less active in preclinical studies, has been approved by the U.S. Food and Drug Administration (FDA) for the reduction of neurological disability and/or frequency of clinical response in patients with SP MS. A phase III trial with pixantrone in relapsed aggressive non-Hodgkin's lymphoma (NHL) is near completion.

"Despite the availability of newer biologic agents, drugs such as mitoxantrone remain an important therapy in relapsing MS. Long term cardiotoxicity remains a major drawback to treating multiple sclerosis with mitoxantrone and imposes a limitation both for selection of patients and for the duration of the treatment," said R.E. Gonsette, M.D., Chairman Fondation Charcot Stichting and principal investigator of the study. "In addition to the potential for lower cardiac toxicity, preclinical studies suggest that pixantrone may provide more effective immune regulation than mitoxantrone, the only currently approved cytotoxic agent for treating MS."

The investigator-sponsored trial (IST) will enroll 20 patients in Belgium, France and Germany.

About the Study

Twenty patients with aggressive RR MS or SP MS who failed to respond to approved immunomodulatory agents (interferons, glatiramer acetate) will be included. The objectives of the study are to determine the efficacy of pixantrone as an immunosuppressive agent based on its ability to decrease the lymphocyte count and to evaluate efficacy in MS based on gadolinium enhanced magnetic resonance imaging. This trial is an open-label, multi-center, non-comparative study of pixantrone administered at a dose of 120 mg/m2 once every 21 days (3 weeks). Four consecutive three-week courses of pixantrone will be administered in order to determine if this regimen results in lymphopenia of less than or equal to 1000/mm3. The doses and the number of infusions will be adapted to leukocyte, granulocyte and thrombocyte counts and possibly reduced.

About Pixantrone

Pixantrone (BBR 2778) is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin's lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed by CTI to improve the activity and safety in treating cancers usually treated with the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone and the risks related to this clinical trial include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of multiple sclerosis, the identification of new risks or limitations of pixantrone that may be discovered in this Investigator Sponsored Trial, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
Susan Callahan
T: 206.272.4472
F: 206.272.4434
E: media@ctiseattle.com
http://www.cticseattle.com/media.htm

Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
http://www.cticseattle.com/investors.htm

SOURCE Cell Therapeutics, Inc.

Web site: http://www.cticseattle.com

Tuesday, March 04, 2008

From Multiple Sclerosis, a Multiplicity of Challenges





By JANE E. BRODY
Published: March 4, 2008

When it comes to understanding, preventing and treating chronic diseases, multiple sclerosis ranks among the most challenging. The word “multiple” is apt in more ways than one.

Various suggested causes include early-life exposure to certain viruses or toxic agents, geographic and dietary influences, inherent immunological defects and underlying genetic susceptibilities.

MS is highly unpredictable. Rarely are any two patients alike in the presentation, duration and progression of symptoms; even the underlying cause of disability in MS is being reconsidered. And rarely do any two patients respond in the same way to a given therapy, be it medically established or alternative. Trial and error is the name of the game, experts say, because it is often not possible to know in advance what will work best for individual patients.

These are the frequent underpinnings of confusion and distrust among those afflicted and their families. They sometimes give rise to claims that the organizations raising large amounts of money to support research and patient services and the scientists studying the disease have no intention of finding a cure, lest it put them out of business. It is a ridiculous notion on its face, since many of those involved in fund-raising and research have watched loved ones suffer and succumb to diseases like MS.

The failure of the medical establishment to solve mysteries like MS also prompts many patients to seek alternative remedies suggested by friends and relatives or found on the Internet. Many of these remedies are harmless, and some may actually be helpful, at least for a time. But when the remedies keep patients from trying the best that modern medicine can offer — or when they interact negatively with established remedies — the result can be a far more rapid downhill course than might otherwise have occurred.

The goal, then, for those considering alternative treatments is to make them complementary to, not competitive with, therapies that have passed muster in well-designed clinical trials.

“People have only one brain and one spinal cord, and what everyone with MS should be doing is optimizing treatment options every single day,” said Dr. Allen C. Bowling, a neurologist at the Rocky Mountain MS Center and author of “Complementary and Alternative Medicine and Multiple Sclerosis.” “Every patient should play the chips for which we have the best evidence. They should take advantage of what conventional medicine has to offer along with unconventional medicine,” as long as the latter does not interfere with the former.

Treatment Options

Multiple sclerosis is an inflammatory autoimmune disease of the central nervous system in which the body’s own immune system attacks the myelin sheath that insulates nerves in the brain and spinal cord, resulting in irreversible damage to the axons that transmit nervous-system signals. About 400,000 people in the United States are affected, twice as many women as men.

MS is typically diagnosed between ages 20 and 40, but evidence indicates that it starts years before the first symptoms of weakness or disability appear. Even without a cure, many treatments are available — like drugs, physical and occupational therapy, exercise and rest — that can ease symptoms and delay the disease’s progression.

In most patients, the disease starts out, and may stay indefinitely, in a relapsing-remitting form that results in gradual progressive disability but is rarely life-threatening. In about 10 percent of patients, the disease is progressive from the outset and life expectancy is reduced.

The goal of therapy is to prevent relapses and the worsening of symptoms. Since symptoms can disappear on their own, large, long-term, scientifically controlled clinical trials are needed to determine what works and what only seems to work initially. Trials are also needed to uncover potentially serious side effects.

Such trials have identified half a dozen substances called immune modulators, five of which have been approved by the Food and Drug Administration as disease-modifying agents. These are Avonex, Betaseron, Copaxane, Novantrone and Rebif.

In her book “Multiple Sclerosis: An Essential Guide for the Newly Diagnosed,” Margaret Blackstone, a medical writer and MS patient, describes Avonex, Betaseron and Rebif as interferon-based treatments administered by injection that seek to calm an overactive immune system. Copaxane, also taken by injection, is an antigen that fools the body into thinking it is the protein in myelin. It is meant to protect the myelin from an immunological attack. Novantrone is an immunosuppressive cancer drug used to treat progressive MS.

A sixth drug, Tysabri, a monoclonal antibody that prevents immune cells from entering the brain, is given intravenously every four weeks. Tysabri was removed from the market in 2004 because of serious complications in three patients. It is now back in clinical trials and available through a special program to those who had found it to be the best treatment for their disease, but last week its makers posted a warning to doctors that it has been found to cause serious liver damage in some patients.

Therapy and Alternatives

Up to 20 percent of patients have a relatively mild form of MS and may not need drug treatment, but it is impossible to predict who they are. Dr. Bowling emphasized the importance of not waiting until neurological defects appear, since they cannot be reversed by any known therapy. He also said that therapies should be tailored to the nature of each patient’s disease and the known activity of the various drugs.

Ms. Blackstone states it is important for patients to recognize an impending relapse — common indicators are fatigue and “a heightened sense of vulnerability, as if the person can tell something bad is going to happen” — and not try to work through a relapse. “It’s better to rest” and “avoid engaging in strenuous activity,” she suggests.

If relapse symptoms warrant, corticosteroids can be used to speed recovery and possibly to delay or prevent another relapse. The other critically important aspect of therapy involves managing symptoms. Depending upon the stage and severity of the disease, symptoms may include fatigue, dizziness, vision changes, spasticity, weakness, tremor, numbness, balance problems, pain, depression, constipation and speech difficulties. In more advanced disease, sexual problems and incontinence are common.

Measures may be taken to reduce disability from these symptoms, like physical, occupational and speech therapy and psychotherapy; avoiding heat; getting adequate rest; and learning to listen to one’s limitations.

At one point or another, most MS patients also seek out, and often benefit from, complementary and alternative medicine, like acupuncture, dietary supplements, biofeedback, meditation, guided imagery, tai chi, cooling therapy, yoga, therapeutic touch and electromagnetic therapy. In his book, Dr. Bowling describes what is known about each of these possible adjuncts to medically established treatments, some of which can be counterproductive or negate the benefits of medication.

This is the first of two columns on multiple sclerosis. Next week: Could a special diet for MS patients be worth trying?

Wednesday, February 27, 2008

Biogen's Tysabri May Cause Liver Injury, U.S. Says (Update2)





By Luke Timmerman and Catherine Larkin

Feb. 27 (Bloomberg) -- Biogen Idec Inc. and Elan Corp.'s multiple sclerosis medicine Tysabri may cause significant liver injury within six days of the first dose, U.S. regulators said.

Patients should stop taking Tysabri if they develop jaundice or other symptoms of liver injury, according to a letter to doctors from the drugmakers that was posted today on the Food and Drug Administration's Web site. Doctors should warn patients about the drug's liver risk, the FDA said.

Tysabri, Biogen's fastest-growing product, generated $129 million in worldwide sales in the fourth quarter and was being taken by 21,000 patients at year-end, according to Biogen. The companies pulled the drug from the market in February 2005 because two patients developed fatal brain infections. The drug was reintroduced in July 2006 after the FDA decided the benefits in slowing multiple sclerosis relapses outweighed the risks.

``At Biogen and Elan, patient safety is our highest priority,'' the companies said in the letter to physicians that is dated this month. ``We are committed to ensuring that health- care professionals continue to receive the necessary information to prescribe Tysabri appropriately.''

Biogen fell 76 cents, or 1.2 percent, to $60.77 at 12:59 p.m. New York time in Nasdaq Stock Market composite trading, after touching $57.95. That 5.8 percent decrease would be the biggest drop in more than two months. The stock has gained 30 percent in the 12 months before today. Elan climbed 11 cents, to 16.59 euros in Dublin trading.

The companies, which market the product together, issued the warning letter after patients developed unusually high levels of liver enzymes in the blood, a sign of liver injury, according to the letter. The injury recurred in some patients after they were given another dose of the drug, ``providing evidence that Tysabri caused the injury,'' according to the letter.

Previous Reports

In July, the FDA cited 28 cases of liver injury associated with Tysabri since November 2004, four of them potentially serious. Elan spokesman Andrew Lewis said at the time the cases were from ``post-marketing experience.'' Tysabri won an additional approval for Crohn's disease in January, after the FDA considered the liver injuries.

Revised prescribing information approved in January includes the liver risks.

Biogen is counting on sales of Tysabri to fuel its growth. The company said this month that it expects 100,000 patients to be taking Tysabri by the end of 2010, which translates to about $2.8 billion in annual sales at current prices.

Biogen is based in Cambridge, Massachusetts. Elan is based in Dublin, Ireland.

To contact the reporters on this story: Luke Timmerman in San Francisco at +1- ltimmerman@bloomberg.net ; Catherine Larkin in Washington at clarkin4@bloomberg.net .

Wednesday, February 20, 2008

MRI findings predict evolution of preclinical multiple sclerosis





Date: Tue, 19 February 2008
by Will Boggs, MD

Patients with subclinical demyelinating lesions fulfilling MRI Barkhof-Tintoré criteria with a normal neurological examination are likely to develop multiple sclerosis (MS), according to a report in the February issue of the Journal of Neurology, Neurosurgery, and Psychiatry.

"Patients who fulfill the Barkhof and Tintoré MRI criteria, combined with CSF study, can be considered high risk for MS and have early treatment," Dr. Christine Lebrun-Frenay from CHU de Nice, France told Reuters Health.

Dr. Lebrun-Frenay and colleagues note that the concept of preclinical MS is now recognized. Silent brain T2 lesions are often seen on incidental MRI, they point out, but patients fulfilling Barkhof-Tintoré criteria are relatively uncommon.

The researchers report clinical and MRI findings after a five-year follow-up in 30 patients with subclinical demyelinating lesions fulfilling Barkhof criteria seen on MRI performed for medical complaints such as headache or trauma.

All patients had a normal examination and biological screening, the authors report, but all patients had increased CSF immunoglobulin levels (including nine with oligoclonal bands) and eight patients had abnormal asymptomatic visual evoked potentials.

Eleven patients clinically converted, including five with optic neuritis, three with diplopia or internuclear ophthalmoplegia, two with paresthesias in the lower limbs, and one with cognitive deterioration.

Four of these patients had their first clinical events during the first year after the first abnormal MRI, three during the second year, three during the third year, and one at five years. The mean time between the abnormal MRI and the clinically isolated syndrome was 2.3 years.

All 17 patients who underwent a second MRI during the first year showed MRI dissemination, the researchers note, as did eight of 12 patients whose second MRI was done between 12 and 24 months.

"For the pre-MS patient, without clinical events but with evidence of dissemination to time and space, medical discussion on the therapeutic options of immunomodulatory agents for reducing the risk of MS should be conducted, with the knowledge that subclinical MS can evolve into relapsing remitting MS in the majority of cases or more rarely into progressive MS," the investigators advise.

"Physicians and especially neurologists must really know Barkhof and McDonald criteria to not overestimate the diagnosis of MS," Dr. Lebrun-Frenay said. "A lot of abnormal MRI with T hyperintensities are classified MS, but a lot of physicians forget what Barkhof and Tintoré said in their principal publications on the way to interpret brain MRI."

If the patient does fulfill the Barkhof-Tintoré criteria, "then a simple workup for other inflammatory conditions would seem to be in order," writes Dr. Jeremy Chataway from St. Mary's Hospital, London, UK in a related editorial. "From there on, time and clinical evaluation would perhaps guide subsequent investigation."


Source: Reuters

Antisense Therapeutics Ltd Licenses ATL1102 to Teva





11 February 2008

• ATL1102 licensed to Teva Pharmaceutical Industries Ltd
• ANP to complete current Phase IIa trial, results due mid-year
• Teva to fund and perform all future development of ATL1102 beyond the current trial

Antisense Therapeutics Ltd. (ASX:ANP) is pleased to announce that it has entered an exclusive, world-wide license agreement with Teva Pharmaceutical Industries Ltd. (Teva), a top 20 global pharmaceutical company, to develop and commercialise ATL1102, a drug discovered by Isis Pharmaceuticals Inc. (Nasdaq: ISIS) and licensed to ANP.

Under the terms of the agreement, ANP will receive an initial $US2m up-front payment. ANP also has the potential to receive payments related to the continued clinical development of ATL1102 for MS upon certain future development milestones, with more significant milestone payments for entry into the market, and sales targets in particular territories. The License includes potential milestone payments of up to $US100m for the MS indication which is contingent upon completion of R&D,
successful commercialization and meeting certain sales milestones and bears inherent risks as does all pharmaceutical R&D. Teva would fund and perform all future development of ATL1102 beyond the current trial, should they decide to continue beyond that point.

If ANP fails to meet a particular development milestone regarding completion of the current ongoing, fully enrolled Phase IIa study by the agreed date in mid 2008, Teva may terminate the agreement and receive a $US2m termination fee.

Royalties are payable on net sales of ATL1102 are in the low double digit range and are tiered according to annual net sales achieved.

The agreement also provides an option for Teva to in-license ATL1102 as an aerosol drug for asthma.

Under a separate Collaboration and License Agreement between ANP and Isis Pharmaceuticals Inc., ANP pays Isis one third of sublicense fees and milestone payments received from Teva as well as a percentage of any royalties ANP receives.

ANP’s Managing Director Mark Diamond said, “We are delighted to have signed this significant licensing deal with one of the world’s leading pharmaceutical companies. Clinical stage deals such as this are subject to very stringent selection criteria and we are particularly pleased that Teva has recognised the drug’s commercial potential. Teva is a company with tremendous expertise in developing drugs, and is our partner of choice.”

ANP will continue to manage and fund the current Phase IIa clinical trial in relapsing-remitting MS patients, which is on track for completion of dosing, unblinding of the clinical trial, and reporting of results in mid 2008.

Antisense Therapeutics makes no representations with respect to the outcome of the Phase IIa trial and, like all other clinical trials in pharmaceutical R&D, there are inherent risks in terms of clinical outcomes, efficacy, cost and timeframes. As such, no assurance can be given that ANP’s drug development efforts will translate to successful commercialisation.

Background Information

ATL1102 is a second generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4), and is currently in
Phase IIa clinical trials as a treatment for MS. In inflammation, white blood cells (leukocytes) move out of the bloodstream
into the inflamed tissue, for example, the CNS in MS, and the lung airways in asthma. The inhibition of VLA-4 may prevent
white blood cells from entering sites of inflammation, thereby halting progression of the disease. VLA-4 is a clinically
validated target in the treatment of MS. Antisense inhibition of VLA-4 has demonstrated positive effects in a number of
animal models of inflammatory disease including MS (Myers et al. J Neuroimmunol 160, p12-24, 2005).

Multiple sclerosis is a life long chronic disease of the central nervous system which is believed to affect as many as 2.5
million people worldwide. Global drug sales for MS exceeded US$5 billion in 2005 and are expected to grow with the
introduction of novel treatment options. There remains a high demand for more effective and better tolerated treatments.
Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and
development company. Its mission is to create, develop and commercialise antisense pharmaceuticals for large unmet
markets. ANP has two drugs in development and two drugs in pre-clinical research. Its lead drug, ATL1102, is in the
advanced stages of a Phase IIa trial as a potential treatment of multiple sclerosis.

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) is exploiting its expertise in RNA to discover and develop novel drugs for its
product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has
18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases.
Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is
developing and commercializing the Ibis T5000™ Biosensor System, a revolutionary system to identify infectious organisms.
Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and
commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the
owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at
http://www.isispharm.com.

For more information:

Website: www.antisense.com.au
Managing Director – Mark Diamond +61 3 9827 8999
Investor Relations – Market Connect Pty. Ltd. (Simon Watkin) +61 3 9863 7797 or 0413 153 272

Monday, February 18, 2008

New MS Drug Target Shows Promise





By Jeffrey Perkel
HealthDay Reporter
Monday, February 18, 2008; 12:00 AM

MONDAY, Feb. 18 (HealthDay News) -- A high-tech molecular fishing expedition has led researchers to two potential therapeutic targets for the treatment of multiple sclerosis.

The data implicate a pathway more typically associated with wound healing -- the blood clotting cascade -- than in the development of multiple sclerosis (MS).

"There is no coagulation component to MS," explained Patricia O'Looney, vice president of biomedical research at the National Multiple Sclerosis Society.

But coagulation factors also play a role in inflammation, whichisa component of the disease, she noted.

"If you can use this pathway and engineer some new drug therapy that will turn on the anti-inflammatory pathway, that could benefit people with MS," O'Looney concluded. "So, this perhaps reveals new therapeutic targets."

The research was published Feb. 17 in the advance online edition of Nature.

In the study, a team led by Dr. Lawrence Steinman of Stanford University School of Medicine grouped MS brain lesions from six autopsied human subjects into three classes based on histological criteria. They then probed those samples, along with samples from two healthy controls, using a technique called mass spectrometry, which essentially identifies the proteins in a tissue based on their mass.

The result was a "proteome" -- a sort of protein index of the tissues. Of the 2,574 proteins the team identified from all the samples, they found a few hundred that were unique to MS. More than half of those proteins were of unknown function, but five were known players in blood coagulation -- a pathway not previously recognized as being involved in the origin and development of the disease. All five were found in a single type of lesion, called a "chronic active plaque."

Puzzled by that observation, Steinman's team then tested whether drugs that targeted two of the five coagulation pathway members, called tissue factor and protein C inhibitor, could alleviate the symptoms of MS in a mouse model of the disease.

They seemed to have succeeded: Mice formerly paralyzed by an MS-like illness regained walking ability after the treatments, the researchers said. "They went from paralysis involving hind limbs to a much more functional score," Steinman said. The effect lasted at least two months, he added.

According to the National Multiple Sclerosis Society, MS affects at least 400,000 Americans. The disease results from loss of the insulating myelin sheath that surrounds nerve fibers, thereby disrupting nerve transmission, and causing damage to the nerve fibers themselves. Symptoms vary from patient to patient but can include blurred vision, slurred speech, loss of coordination and paralysis. Disease course can also vary, with four distinct disease forms recognized, the most common of which is relapsing remitting MS.

According to O'Looney, that variability is "the biggest challenge" of the disease.

"The symptoms may vary from person to person, the disease course will be variable, and we don't understand why there is this difference among people with MS," she said.

"And so," she added, "what is terrific about this study is that it compares the different forms of MS."

Six MS treatments have been approved for use by the US Food and Drug Administration, but there is as yet no cure for the disease, according to O'Looney. The two drugs Steinman used have been approved by the FDA for use in treating other diseases, however. Hirulog is an anti-coagulant protein fragment derived from leeches; Xigris is a recombinant form of activated protein C, for use against severe sepsis.

Those approvals should give researchers a head-start in getting these compounds into clinical testing for MS, Steinman said. "We can already jump past toxicity testing, because they are already approved," he noted.

But that doesn't mean doctors should administer these drugs to their MS patients right now, Steinman cautioned.

"It needs to be tested in clinical trials. We need evidence, and these drugs have serious potential side effects," he said. "But organized, well-run clinical trials should be done, because these drugs may be of immense potential benefit to people with MS."

Praising the study's use of donated human samples, O'Looney added that, "it's a perfect example of how we can learn so much from the use of tissue samples. We are so indebted to people with MS who leave the message that their bodies are available to researchers. So, this is the perfect example of how valuable that is. That's what drove this study."

More information

For more on multiple sclerosis, visit the National Multiple Sclerosis Society.

SOURCES: Larry Steinman, M.D., professor, neurology and neurological sciences, and chair, Interdepartmental Program in Immunology, Stanford University School of Medicine; Patricia A. O'Looney, Ph.D., vice president of biomedical research, National Multiple Sclerosis Society; Feb. 17, 2008, advance online publication,Nature

© 2008 Scout News LLC. All rights reserved.

Friday, February 15, 2008

Marijuana ups MS problems

[Posted: Fri 15/02/2008]

People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, the results of a new study indicate.

Around 6,000 people in Ireland have MS, which affects the brain and the spinal cord. There is currently no cure and the condition is characterised by a slowly progressing disablement.

According to the Canadian researchers, these findings are important because a ‘significant minority’ of people with MS smoke marijuana as a treatment for the disease, ‘even though there are no scientific studies demonstrating that it is an effective treatment for emotional difficulties’.

The study involved 140 people with MS. Of these, 10 had smoked marijuana within the last month and were considered current users. They were compared to people with MS who did not smoke marijuana.

The participants were evaluated for emotional problems and psychiatric disorders, including depression and anxiety. They were also evaluated in other areas such as speed at processing information and memory.

The researchers found that marijuana smokers performed 50% slower in information processing tests, compared to MS patients who did not smoke marijuana.

There was also a significant link between smoking marijuana and emotional problems such as depression and anxiety,

“Since marijuana can induce psychosis and anxiety in healthy people, we felt it was especially important to look at its effects on people with MS. This is the first study to show that smoking marijuana can have a harmful effect on the cognitive skills of people with MS”, said lead researcher Dr Anthony Feinstein of the University of Toronto.

Details of these findings are published in the medical journal, Neurology.

Rituxan Shows Promise for MS





Cancer, Arthritis Drug May Help People With Multiple Sclerosis
By Salynn Boyles

WebMD Medical News Reviewed by Louise Chang, MD

Feb. 13 -- The novel cancer and rheumatoid arthritis drug Rituxan may prove to be a highly effective treatment for the most common form of multiple sclerosis, if results from a small, phase II trial are confirmed.

In the study, sponsored by the drug's manufacturers, patients with relapsing-remitting MS who were treated with a single course of Rituxan showed rapid reductions in the inflammatory brain lesions that are a hallmark of the disease.

And after nearly a year of follow-up, half as many patients treated with the drug had experienced clinically significant relapses as patients in the placebo arm of the study.

If the findings are confirmed in larger, phase III studies, the Rituxan research opens a new frontier for the study of the cause and treatment of MS, says lead author Stephen L. Hauser, MD, of the University of California, San Francisco (UCSF).

The study is published in the Feb. 14 issue of The New England Journal of Medicine.

"No matter what happens with Rituxan down the road, this represents a paradigm shift that has profound implications for our understanding of MS," he tells WebMD.

T Cells and B Cells
The leading treatments for MS target the T cells. The thinking has been that T-cell-mediated inflammation sends the immune system into overdrive, causing the body to attack itself.

MS occurs when this attack targets the protective insulation known as myelin, which protects nerve fibers of the central nervous system. Myelin helps nerve fibers transmit electrical signals.

Instead of targeting T cells, Rituxan targets specific immune cells called B cells.

Studies by the UCSF researchers and others suggest that B cells and related pathways play a key role in destroying myelin.

The study included 104 patients with relapsing-remitting multiple sclerosis treated with either two infusions of Rituxan separated by two weeks, considered one course of treatment, or placebo infusions.

The patients were followed for 48 weeks, and brain imaging was performed to look for areas of inflammatory lesions at weeks 4, 12, 16, 18, and 24.

The imaging revealed dramatic and very rapid improvements in these lesions.

By week 24, the Rituxan-treated patients showed 91% fewer lesions, compared with the placebo-treated patients, and the results were similar at week 48.

"What we found so stunning was not only that the drug worked, but that it worked almost immediately," Hauser says.

The patients who got Rituxan showed improvement in lesions with the first post-infusion MRI scan, taken just weeks after treatment ended.

"This could only have happened if the B cells themselves are the culprit and not the antibody," he says. "It sends us back to the lab to discover what it is about the B cell, independent of its impact on antibodies, that is at the center of what causes MS flares."

Rituxan Safety Concerns
Hauser says there were few treatment-related side effects among the patients in the study, but questions about the long-term safety of Rituxan remain.

Rituxan is approved for the treatment of non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis.

Use of the drug has been linked to a rare but fatal brain infection known as progressive multifocal leukoencephalopathy (PML). But it is not clear if PML is caused by the drug or by the patients' underlying disease.

Until more is known and until Rituxan is approved for the treatment of MS, patients with multiple sclerosis should not use it, says John Richert, MD, the National Multiple Sclerosis Society's executive vice president for research and clinical programs.

"We really want to discourage off-label use," he tells WebMD. "We just don't know enough about its long-term safety."

But Richert agrees that the early findings offer the hope of a new direction in the study and treatment of MS.

"Within the limitations of what you would expect with a small trial of short duration, the (UCSF) results are very exciting," he says. "We are cautiously optimistic that the phase III trials will show the same degree of efficacy."

SOURCES:
Hauser, S.L., The New England Journal of Medicine, Feb. 14, 2008; vol 358: pp 676-688.
Stephen L. Hauser, MD, department of neurology, University of California, San Francisco.
John Richert, MD, executive vice president for research and clinical programs, National Multiple Sclerosis Society.
© 2008 WebMD, LLC. All rights reserved.

Multiple Sclerosis Drug May Be Linked to Melanoma





Doctors report 2 cases of the deadly skin cancer developing in patients taking Tysabri

By Amanda Gardner
Posted 2/6/08

WEDNESDAY, Feb. 6 (HealthDay News) -- Almost immediately after a 46-year-old woman with multiple sclerosis received her first dose of the drug Tysabri, a mole that had been on her shoulder for years suddenly took on a dangerous new character.

It turned out to be a melanoma that spread like wildfire. The woman now has just a few months to live.

At almost the same time, a 45-year-old woman who also has multiple sclerosis developed melanoma in her retina after receiving several doses of Tysabri. She had a family history of melanoma and also had atypical moles on her body; the mole on her retina went back at least nine years.

Although these are just two -- albeit dramatic -- examples, the authors of a letter in the Feb. 7 issue of the New England Journal of Medicine are cautioning doctors who care for MS patients to keep this potential risk in mind.

"Neurologists who have patients who report a family history of melanoma or have funny moles should send them to a dermatologist first. Don't just start them on drugs [Tysabri]," said Dr. John Thomas Mullen, co-author of the letter and a surgical oncologist with Beth Israel Deaconess Medical Center, in Boston.

"I can't say it's cause-and-effect definitively because it's just an observation, but the first patient had had that mole forever. She took the drug and almost instantaneously the lesion changed," added Mullen, who saw both patients.

"We don't know if the two are related right now," said Patricia O'Looney, vice president of biomedical research at the National Multiple Sclerosis Society. "There are so many people taking Tysabri, we should go forward with caution... One should always consult with their doctor and go over their personal family history and decide what is best."

Tysabri (natalizumab), a monoclonal antibody that helps treat autoimmune disorders such as MS and Crohn's disease, has had a clouded history. It first received U.S. Food and Drug Administration approval in November 2004, only to be pulled from the market three months later after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy.

In June 2006, the FDA allowed the drug back on the market but with strict conditions governing its use.

Just last month, the FDA approved Tysabri to treat people with a moderate to severe form of Crohn's disease.

But there is basic science to support Mullen's observations.

One of the participants in an earlier study of Tysabri had developed (and subsequently died of) a metastatic melanoma that appeared as soon as he got his first dose of the drug, Mullen said.

And in a study done before Tysabri received FDA approval, melanomas in mice that were given the drug had an increased tendency to detach from the primary tumor and spread.

Tysabari may have a dampening effect on the immune system that encourages the formation of the potentially deadly skin cancer, the letter stated.

And now that Tysabri has been approved for people with Crohn's disease, more people may be at risk, although those with no family history of melanoma and no moles probably don't need to worry, Mullen said.

"Doctors should ask for a family history of melanoma and do a quick skin check," he said. "Tysabri isn't the only drug in our arsenal. You could give the patient something else if you were concerned about that."


Copyright © 2008 ScoutNews, LLC. All rights reserved.

Thursday, January 31, 2008

Acorda Therapeutics Announces Successful Thorough QT Study of Fampridine-SR




Fampridine-SR Not Associated with QT Changes

Company to Host Conference Call at 8:30 am Eastern Time Today

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 28, 2008--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced results from a thorough QT study of Fampridine-SR. This study evaluated the potential to cause an increase in the electrocardiographic QT interval. Fampridine-SR, at both therapeutic and supratherapeutic doses, was found to be no different than placebo. The U.S. Food and Drug Administration requires thorough QT studies for all new drugs seeking regulatory approval, as increases in the QT interval (corrected for changes in heart rate, or QTc) may signify an increased risk of developing malignant cardiac arrhythmias.

This double-blind trial compared the electrocardiographic effects of Fampridine-SR, given at a therapeutic (10 mg twice daily) and supratherapeutic dose (30 mg twice daily), to placebo and moxifloxacin in 208 healthy subjects. Moxifloxacin is a positive control known to increase the QT interval.

The placebo-corrected QTc mean change from baseline (using the individual correction method for heart rate, or QTci) for the therapeutic and supratherapeutic doses of Fampridine-SR were 0 and 1 milliseconds, respectively. Moxifloxacin demonstrated QT prolongation consistent with previous clinical experience. In addition to no changes in the mean QTci interval, none of the subjects in the Fampridine-SR cohort showed increases in the QTci of greater than 30 milliseconds, nor did any of the Fampridine-SR subjects display a QTci interval that exceeded 480 milliseconds at any time.

Ron Cohen, Acorda's President and Chief Executive Officer, commented, "We are delighted with the results of this QT study, and are looking forward to completing our second Phase 3 trial of Fampridine-SR in multiple sclerosis patients in the second quarter of this year."

The company will host a conference call Monday, January 28, 2008 at 8:30 a.m. Eastern Time. To participate, please dial 866-800-8652 (domestic) or 617-614-2705 (international) and reference the access code 87165145. A replay of the call will be available from 11:00 a.m. Eastern Time on January 28, 2008 until February 28, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 18388394. The archived teleconference will be available for 30 days in the Investor Relations section of the Acorda website at http://www.acorda.com.

About Fampridine-SR

Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine

(4-aminopyridine or 4-AP). Laboratory studies have shown that fampridine can improve the communication between damaged nerves, which may result in increased neurological function. Fampridine-SR is currently being studied in a Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ability in people with multiple sclerosis (MS).

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda's lead clinical product, Fampridine-SR, is in a Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, failure to protect its intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from its preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

CONTACT: Acorda Therapeutics
MEDIA:
Jeff Macdonald, 914-347-4300 ext. 232
jmacdonald@acorda.com
or
INVESTOR RELATIONS:
Molly Newton, 914-347-4300 ext. 203
mnewton@acorda.com

SOURCE: Acorda Therapeutics, Inc.

Blood Flow May Be Key Player in Neural Processing

January 24, 2008

An M.I.T. scientist believes that if blood flow actually impacts neuronal behavior, the fMRI would be an even more powerful tool for diagnosing disorders such as Alzheimer's and schizophrenia

By Nikhil Swaminathan

Blood racing through a brain region's web of vessels is a sign that nerve cells in that locale have kicked into action. The blood rushes to active areas to supply firing neurons with the oxygen and glucose they need for energy.

It is this blood flow, which can last up to a minute, that scientists track in functional magnetic resonance imaging (fMRI) to determine which brain areas are responding to different stimuli. But a new theory could pave the way for a reinterpretation of fMRI images, elevating their measurements to the evaluation of actual neuronal processing rather than the subsequent blood flow that indirectly indicates it, and thereby enhancing the fMRI's usefulness in diagnosing neurological problems.

Christopher Moore, an assistant neuroscience professor at the Massachusetts Institute of Technology's McGovern Institute for Brain Research, detailed his hypothesis in a recent article published in the Journal of Neurophysiology. In essence, it suggests blood's role in the cortex (a key brain processing center), specifically, is more than just bringing nutrients to the cell, it can also alter the activity of local neuronal circuits. For instance, in experiments in his lab, Moore has seen that there is more blood flow can arrive in an area that processes information from a presented stimulus to a certain sense (e.g. touch, visual, auditory) prior to the appearance of the stimulus, implying that the flow can prime a circuit for activity, as well.

Researchers estimate that blood flow in areas of the brain increases by 40 percent when neurons start to fire (or send out electronic impulses), whereas the corresponding metabolic rate of the cells only increases by 4 percent, meaning the cell only needs a tenth of the blood it is supplied to reenergize. "[Neuroscientists] call this discrepancy an 'uncoupling' between flow and metabolism," says Kenneth Kwong, an associate professor in radiology at Harvard Medical School and the researcher, along with Seiji Ogawa, who is generally credited with developing fMRI.

Moore believes that the reason for the discrepancy could be that blood not only nourishes cells but may be intimately involved in the information processing.

If true, Moore says, blood should be factored into any model of neuronal processing—how nerve cells in the brain are activated, how impulses are transmitted between them, how long activity lasts, and how it is terminated. In addition to changing what fMRI is actually measuring, such models could potentially provide new clues to causes of enigmatic disorders such as Alzheimer's disease, multiple sclerosis and schziophrenia—potentially paving the way for treatments that involve correcting blood flow as well as (or rather than) chemical deficiencies.

"Historically, fMRI researchers have to be a little apologetic because they're not looking [directly] at the neuron," Moore says. "fMRI would stop being a second-class citizen; instead it would make fMRI a much more interesting tool…a Heisenberg sort of thing [referring to how the act of observing a quantum state changes it], where what you're looking at is actually a part of the computation going on." Further, scans taken over a number of years could help predict neurodegeneration, if vasculature in a particular brain region begins to weaken. Preliminary data already suggest this is the case for many neurological disorders such as schizophrenia.

The so-called hemo-neural hypothesis plays out in three tissue types: neurons, the blood vessels that feed them, and astrocytes, the star-shaped nerve cells that support and maintain neurons. (Astrocytes, the feet of which are splayed on blood vessels, also help maintain the endothelial cells that line the vessels as well as make up the semipermeable blood–brain barrier responsible for keeping chemicals in the blood from seeping into the brain unless they are needed for metabolism or some other function.)

According to Moore, the vasculature thus directly or indirectly (via astrocytes) influences neurons. He notes that substances in blood may modulate neuron activity. The most likely candidate, he says, is nitric oxide (NO), which easily crosses the blood–brain barrier and has been shown both in brain slices and in animal models to excite (and in some cases dampen) neuronal action. Blood vessels also affect neurons via thermal and mechanical stress. Increased blood flow can alter the local temperature in a brain region. For instance, a decrease of just one degree Celsius can lead to suppressed firing rates, in some circumstances. As a rule, blood flow changes increase the temperature in outer brain areas, while decreasing the temperature of more central regions. Pressure and volume, meanwhile, within the blood vessels can change the amount that the vessels physically impact the membranes of brain cells. If pressure or volume were to increase, a vessel could bulge, blocking receptors or ion channels and thereby causing a decrease in a neuron's electrical activity.

A change in blood flow could also trigger astrocytes to release certain hormones or neurotransmitters. "If anything is going on in the blood vessel," Moore says, "the glia (astrocytes and other nonneuronal nerve cells) is in a great position to sense it." For instance, astrocytes might secrete the excitatory neurotransmitter glutamate, which binds to neurons and allows ion exchanges that cause cells to fire.

Preliminary data from Moore's lab, involving a drug that selectively binds to receptors on blood vessels (and can open or close them), has shown neurons may become more active when blood flow increases. The M.I.T. group is now trying to develop light-activated ion channels on muscle cells, which they could then selectively control to induce changes in blood flow.

The theory "brings up something that a lot of people have been ignoring—thinking that blood vessels are tubes," says Edith Hamel, a professor of neurology at McGill University in Montreal, who believes that Moore's theory will one day prove true. "But, they are live cells…like neurons." She likens the vasculature interaction within the nervous system to that of the infrastructure of a highway system. "We have always been looking at the highway going out of the city," she says. "We need to look at the one coming into the city, as well."

Rick Buxton, a radiology professor at the University of California, San Diego, finds the idea intriguing, but he is "skeptical that blood flow is really an important modulator." In his interpretation, the rush of blood is necessary to maintain oxygen levels in the tissue, because neurons may take in oxygen at a slower rate than normal when blood is gushing by; therefore, more is needed to properly nourish the cells. Another possible way to account for the excess blood flow, according to some researchers, is that it may help carry away some of the heat generated by neuronal firing. "If there's some low level of neuromodulation in there, [as well], that's good," Buxton adds.

Moore notes that if the blood is responsible for a relatively low level of neuromodulation, it could still be significant. "Let's say that blood flow accounts for 5 percent of the variance of activity in cortical neurons," he supposes. "Five percent of the neuron's work—that's huge, if it's pushing around excitability by that scale."

Moore's theory is supported by research into neurodegenerative and mental disorders. Constantino Iadecola, a professor of neurology and neuroscience at Weill Cornell Medical College in New York City, for instance, has found a link between blood vessels and neurons in his work on Alzheimer's disease.

"We have provided evidence that the vasculature is the first thing that goes," he says, noting that Alzheimer's-associated dementia was previously split into two groups: vascular-induced (in which neurons die due to improper blood flow) and neurodegeneration-induced (with vasculature collapse following nerve cell death). "What's emerging from the literature now is that the [vessel changes occur] at least as early or earlier than the neuronal changes."

Abnormal blood flow has also been linked to epilepsy, which is caused by overactive neurons. And, according to Moore, an impoverished blood supply is usually noted in the areas of schizophrenia sufferers' brains that go awry in the disorder.

Moore envisions that in the future research on treatments for mental disorders will focus on potential drugs designed to maintain proper neuronal function by targeting vasculature. "It would be beneficial to upregulate and downregulate blood flow," he says, "the same way as it's beneficial to upregulate or downregulate [the neurotransmitter] dopamine in schizophrenics."